{"id":"W2879638111","doi":"10.2196/11191","title":"Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial","year":2018,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Prostate cancer; Abiraterone; Medicine; Abiraterone acetate; Protocol (science); Oncology; Randomized controlled trial; Androgen deprivation therapy; Internal medicine; Cancer; Alternative medicine; Androgen receptor","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02505969,0.004955673,0.006694595,0.001444875,0.002937959,0.003191776,0.004210303,0.004484074,0.03494973],"category_scores_gemma":[0.01948935,0.002016384,0.005416363,0.002351033,0.002909769,0.002460734,0.001988559,0.008297262,0.008180931],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00486896,"about_ca_system_score_gemma":0.0149709,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002013962,"about_ca_topic_score_gemma":0.005087864,"domain_scores_codex":[0.9859847,0.009712677,0.00105584,0.001058633,0.001152536,0.001035569],"domain_scores_gemma":[0.9909111,0.001588032,0.002194022,0.001222693,0.001937934,0.002146165],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9505145,0.008470864,0.0006615588,0.005609049,0.001800186,0.0001555593,0.0002103205,0.00154497,0.002365079,0.001489363,0.01233402,0.01484448],"study_design_scores_gemma":[0.9520503,0.02166425,0.001489326,0.0008360064,0.0007843493,0.00007454462,0.00007003387,0.001142334,0.0005546791,0.001143843,0.02013904,0.00005120461],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.00627361,0.0006857367,0.001844067,0.0005138037,0.0004805888,0.9863208,0.00205681,0.0001457326,0.00167897],"genre_scores_gemma":[0.006665256,0.0004011922,0.003603865,0.0004444862,0.0001123214,0.9869215,0.0007774284,0.00001581093,0.001058197],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.03494973,"threshold_uncertainty_score":0.1325299,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3228273930777455,"score_gpt":0.6162267959688664,"score_spread":0.2933994028911209,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}